Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Sep-24-22 | Jun-25-22 | Mar-26-22 | Dec-25-21 | Sep-25-21 | Jun-26-21 | Mar-27-21 | Dec-26-20 |
| | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues: |
| Breast Health | 1,227.6 | 1,286.8 | 1,353.0 | 1,378.9 | 1,352.3 | 1,307.1 | 1,182.1 | 1,153.6 |
| Diagnostics | 3,018.5 | 3,334.4 | 3,439.8 | 3,517.2 | 3,695.0 | 3,797.1 | 3,663.8 | 2,918.5 |
| GYN Surgical | 523.0 | 511.6 | 501.4 | 498.3 | 488.0 | 466.3 | 389.9 | 381.1 |
| Skeletal Health | 93.6 | 93.3 | 97.5 | 99.2 | 97.0 | 92.1 | 81.4 | 82.5 |
| Total revenues [+] | 4,862.7 | 5,226.1 | 5,391.7 | 5,493.6 | 5,632.3 | 5,662.6 | 5,317.2 | 4,535.7 |
| Products | | 3,408.6 | 3,566.7 | 3,677.3 | | 3,829.4 | 3,535.8 | 2,780.6 |
| Services | | 500.9 | 508.4 | 499.7 | | 486.3 | 434.5 | 408.2 |
| Revenue growth [+] | -13.7% | -7.7% | 1.4% | 21.1% | 49.1% | 71.8% | 59.9% | 33.9% |
| Breast Health | -9.2% | -1.6% | 14.5% | 19.5% | 17.4% | 8.4% | -9.5% | -12.6% |
| Diagnostics | -18.3% | -12.2% | -6.1% | 20.5% | 75.8% | 158.3% | 194.8% | 139.1% |
| GYN Surgical | 7.2% | 9.7% | 28.6% | 30.8% | 29.7% | 19.4% | -13.6% | -14.9% |
| Skeletal Health | -3.5% | 1.3% | 19.8% | 20.2% | 19.6% | 5.4% | -15.7% | -15.0% |
| Cost of goods sold [+] | 1,518.3 | 294.6 | 332.2 | 310.3 | 276.7 | 456.4 | 377.6 | 300.2 |
| Cost of services | | 287.5 | 280.7 | 273.1 | | 264.6 | 238.7 | 226.2 |
| Gross profit | 3,344.4 | 4,931.5 | 5,059.5 | 5,183.3 | 5,355.6 | 5,206.2 | 4,939.6 | 4,235.5 |
| Gross margin | 68.8% | 94.4% | 93.8% | 94.4% | 95.1% | 91.9% | 92.9% | 93.4% |
| Selling, general and administrative [+] | 1,037.9 | 1,075.9 | 1,091.7 | 1,040.2 | 994.4 | 921.3 | 870.1 | 827.3 |
| Sales and marketing | 630.4 | 630.1 | 620.5 | 580.6 | 561.2 | 527.8 | 488.6 | 467.7 |
| General and administrative | 407.5 | 445.8 | 471.2 | 459.6 | 433.2 | 393.5 | 381.5 | 359.6 |
| Research and development | 283.4 | 283.9 | 287.8 | 289.8 | 276.3 | 256.8 | 242.9 | 220.7 |
| Other operating expenses | 392.3 | 1,665.5 | 1,640.9 | 1,624.4 | 1,601.9 | 1,347.5 | 1,316.2 | 1,302.0 |
| EBITDA [+] | 2,072.3 | 2,358.9 | 2,472.1 | 2,651.0 | 2,889.9 | 3,064.0 | 2,886.3 | 2,259.9 |
| EBITDA growth | -28.3% | -23.0% | -14.4% | 17.3% | 92.5% | 117.7% | 108.7% | 127.0% |
| EBITDA margin | 42.6% | 45.1% | 45.9% | 48.3% | 51.3% | 54.1% | 54.3% | 49.8% |
| Depreciation | 176.5 | 178.3 | 91.4 | 89.2 | 88.0 | 84.5 | 82.3 | 82.6 |
| EBITA | 1,895.8 | 2,180.6 | 2,380.7 | 2,561.8 | 2,801.9 | 2,979.5 | 2,804.0 | 2,177.3 |
| EBITA margin | 39.0% | 41.7% | 44.2% | 46.6% | 49.7% | 52.6% | 52.7% | 48.0% |
| Amortization of intangibles | 265.0 | 274.4 | 341.6 | 332.9 | 318.9 | 298.9 | 293.6 | 291.8 |
| EBIT [+] | 1,630.8 | 1,906.2 | 2,039.1 | 2,228.9 | 2,483.0 | 2,680.6 | 2,510.4 | 1,885.5 |
| EBIT growth | -34.3% | -28.9% | -18.8% | 18.2% | 120.7% | 164.9% | 159.3% | 238.6% |
| EBIT margin | 33.5% | 36.5% | 37.8% | 40.6% | 44.1% | 47.3% | 47.2% | 41.6% |
| Non-recurring items | -9.4 | -32.6 | 5.6 | -7.3 | 2.6 | 6.9 | 4.3 | 19.8 |
| Interest expense, net [+] | 82.1 | 89.7 | 90.6 | 89.8 | 92.3 | 94.6 | 100.3 | 109.3 |
| Interest expense | 95.1 | 93.7 | 92.6 | 91.3 | 93.7 | 96.0 | 101.8 | 111.8 |
| Interest income | 13.0 | 4.0 | 2.0 | 1.5 | 1.4 | 1.4 | 1.5 | 2.5 |
| Other income (expense), net [+] | 30.0 | 6.2 | 1.5 | 4.1 | -27.1 | -11.6 | -7.4 | -19.6 |
| Gain (loss) on debt retirement | | | | -0.7 | | | | -21.6 |
| Other | 30.7 | 6.9 | 2.2 | 4.8 | -5.5 | 10.0 | 14.2 | 2.0 |
| Pre-tax income | 1,588.1 | 1,855.3 | 1,944.4 | 2,150.5 | 2,361.0 | 2,567.5 | 2,398.4 | 1,736.8 |
| Income taxes | 286.1 | 343.2 | 392.6 | 435.0 | 491.3 | 533.0 | 495.6 | 358.6 |
| Tax rate | 18.0% | 18.5% | 20.2% | 20.2% | 20.8% | 20.8% | 20.7% | 20.6% |
| Net income | 1,302.0 | 1,512.1 | 1,551.8 | 1,715.5 | 1,869.7 | 2,034.5 | 1,902.8 | 1,378.2 |
| Net margin | 26.8% | 28.9% | 28.8% | 31.2% | 33.2% | 35.9% | 35.8% | 30.4% |
| |
| Basic EPS [+] | $5.17 | $5.97 | $6.10 | $6.69 | $7.26 | $7.85 | $7.32 | $5.28 |
| Growth | -28.8% | -24.0% | -16.7% | 26.8% | 72.2% | 322.0% | 334.0% | 1597.5% |
| Diluted EPS [+] | $5.12 | $5.92 | $6.04 | $6.63 | $7.19 | $7.78 | $7.26 | $5.24 |
| Growth | -28.7% | -24.0% | -16.8% | 26.5% | 71.4% | 319.7% | 332.5% | 1591.2% |
| |
| |
| Shares outstanding (basic) [+] | 251.8 | 253.2 | 254.6 | 256.3 | 257.6 | 259.0 | 259.9 | 261.1 |
| Growth | -2.2% | -2.2% | -2.1% | -1.8% | -2.2% | -2.3% | -2.8% | -2.9% |
| Shares outstanding (diluted) [+] | 254.2 | 255.6 | 257.0 | 258.8 | 260.2 | 261.4 | 262.0 | 263.0 |
| Growth | -2.3% | -2.2% | -1.9% | -1.6% | -1.8% | -1.8% | -2.4% | -2.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|